Seeking Alpha

Sales of Biogen's (BIIB +1.5%) Tecfidera grow 12% W/W, something Wells Fargo says suggests...

Sales of Biogen's (BIIB +1.5%) Tecfidera grow 12% W/W, something Wells Fargo says suggests "there is still … pentup demand working through the system." Furthermore, it appears "the steady-state W/W prescription level has not been reached yet," analyst Brian Abrahams notes, adding that he still sees "Tecfidera Q2 sales comfortably beat[ing] consensus."
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs